{ "Enobosarm and Semaglutide for Weight Loss in Older Adults", "This study is testing if adding enobosarm to semaglutide (Wegovy), a common weight-loss medication, helps older adults lose more weight than semaglutide alone. Enobosarm is a drug that aims to increase muscle and reduce fat. We are looking for 200 participants aged 65 to 100 years old who are overweight or have obesity. Women must be postmenopausal. The main goal is to see how much total body weight changes after about 1.5 years (476 days) when combining enobosarm with semaglutide, compared to semaglutide alone. The study status is currently unclear.", "design": "This is a randomized, double-blind, and placebo-controlled study with 200 participants. You would be randomly assigned to receive either semaglutide plus enobosarm, or semaglutide plus a placebo (an inactive substance).", "commitments": "You would start semaglutide injections on Day 1. The study measures your body weight at 68 weeks (476 days).", "compensation": "Not stated in the trial record.", "follow_up": "There will be a safety follow-up visit about 30 days after your last dose of the study drug.", }

Study design

Not specified.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.